Stockwinners Market Radar for March 31, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:33 EDT Box Office Battle: 'Dumbo' opens to disappointing $45M - Disney's (DIS) "Dumbo" opened to a disappointing $45M from 4,529 theaters. Overseas, the Tim Burton's live-action update of the classic 1941 animated film about a baby elephant with magical ears opened to $71M for a global start of $116M. "Dumbo" sports an A- CinemaScore and a 50% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: Comcast (CMCSA, CMCSK) subsidiary Universal's "Us" fell to number 2, with another $33.6M from 3,743 theaters, a decline of just 53%. Behind it was Marvell and Walt Disney Studio's "Captain Marvell," earning $21M as it prepares to cross the $1B mark at the global box office later this week. Lionsgate's (LGF.A) "Five Feet Apart" placed number four with another $6.3M. Rounding out the top five, the anti-abortion drama "Unplanned" overperformed in its launch with $6.1M from 1,059 theaters, the second-best start ever for faith-based distributor Pure Flix behind "God's Not Dead 2." Other publicly traded companies in filmmaking include Viacom (VIAB), AT&T (T) and Sony (SNE).

16:14 EDT Neon Therapeutics presents updated data from Phase 1b NT001 trial - Neon Therapeutics presented updated data describing the immune and pathologic markers associated with durable clinical benefit in patients enrolled in NT-001, an ongoing Phase 1b clinical trial evaluating NEO-PV-01 in combination with nivolumab. The data were highlighted in an oral presentation at the American Association for Cancer Research Annual Meeting in Atlanta. NEO-PV-01 is a personal neoantigen vaccine custom-designed and manufactured based on the neoantigens identified by Neon's proprietary bioinformatics engine, RECON, as being the most therapeutically relevant for an individual patient. The data presented, which reflect a cutoff date of August 31, 2018, include 23 patients with metastatic melanoma who received at least one dose of NEO-PV-01 and who either remained progression-free or had progressed by week 36 after the initiation of anti-PD-1 therapy. Patients who did not progress by 36 weeks were classified as having durable clinical benefit. The data indicate that RECON-based prediction of neoantigen quality correlates with DCB and serves as clinical validation for RECON's ability to identify therapeutically relevant neoantigens. The analysis presented at AACR both confirms mechanism of action of NEO-PV-01 and highlights new data on the relationships between multiple histological and molecular markers and DCB in the melanoma cohort.

14:12 EDT Atara's collaborator presents Phase 1 study results in Advanced Mesothelioma - Atara Biotherapeutics announced that the company's collaborators at Memorial Sloan Kettering Cancer Center presented encouraging results from an ongoing MSK investigator-sponsored Phase 1 clinical study of a mesothelin-targeted CAR T immunotherapy for patients with mesothelin-associated malignant pleural solid tumors, primarily mesothelioma, who progressed following prior standard platinum-containing chemotherapy. Mesothelin-targeted, autologous CAR T cells delivered regionally were well-tolerated and showed anti-tumor activity in combination with pembrolizumab, a PD-1 checkpoint inhibitor. The Phase 1 clinical study recruited 21 patients, 19 with malignant pleural mesothelioma, one with metastatic lung cancer and one with metastatic breast cancer, who received a median of 3 prior treatment regimens, to evaluate the safety and potential anti-tumor activity of a CD28-costimulated, mesothelin-targeted autologous CAR T immunotherapy. The study included six dose cohorts with administration directly to the tumor site using regional delivery techniques, initially at a low CAR T dose without lymphodepleting chemotherapy, followed by increasing CAR T dose cohorts with lymphodepletion. A subset of these patients was subsequently treated with pembrolizumab, a PD-1 checkpoint inhibitor. Mesothelin-targeted, autologous CAR T administration was found to be generally well-tolerated with no CAR T-related toxicities higher than grade 2 observed based on monitoring multiple clinical, radiological, and laboratory parameters. CAR T cells were found to be persistent in the peripheral blood for 13 of the 21 patients during the 38-week evaluation, and their presence was associated with evidence of tumor regression on imaging studies. Best overall response rate for a subset of 11 MPM patients with minimum follow-up time of 3 months who also received pembrolizumab and lymphodepleting chemotherapy was 72% including 2 durable complete metabolic responses on PET imaging and 6 partial responses. Six of the 11 patients in this subset were programmed cell death ligand 1 negative, defined as undetectable expression of PD-L1 in tumor cells by immunohistochemistry, with 4 of the 8 total responses observed in PD-L1 negative patients. Following progression on standard platinum-containing chemotherapy, the expected ORR for patients with MPM treated with a checkpoint inhibitor is estimated between 5%-29% with one patient achieving a CR across multiple studies. MSK is also investigating mesothelin-targeted CAR T cells for patients with mesothelin-associated advanced breast cancer. Additional results from these ongoing studies are expected to be presented at upcoming scientific congresses.